Azra H. Ligon, PhD, FACMG

Получаване на мой собствен потребителски профил

Позовавания

	Всички	От 2019
Позовавания	34675	16677
h-индекс	69	50
i10-индекс	106	88

3300

1650

825

2475

199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202 229 250 294 320 311 325 326 346 327 316 411 542 740 976 1140 1286 1773 2151 2517 2803 2562 3045 3202 2904 2628 2304

Публичен достъп

Преглед на всички

66 статии

1 статия

налични

неналични

Въз основа на изисквания при финансирането

Съавтори

Keith L. LigonAssociate Professor, Harvard Medical SchoolПотвърден имейл адрес: dfci.harvard.edu
Scott RodigProfessor of Pathology, Brigham & Women's HospitalПотвърден имейл адрес: bwh.harvard.edu
Sandro Santagata MD PhDBWH Pathology | HMS Laboratory of Systems Pharmacology | HMS Department of SysBioПотвърден имейл адрес: bics.bwh.harvard.edu
Gordon FreemanDana-Farber Cancer Institute, Harvard Medical SchoolUnknown affiliationПотвърден имейл адрес: dfci.harvard.edu
Rameen BeroukhimDana-Farber Cancer Institute, Harvard Medical SchoolПотвърден имейл адрес: broadinstitute.org
Wenya Linda BiDept. of Neurosurgery, Brigham and Women's HospitalПотвърден имейл адрес: partners.org
Ian F. Dunn, MD, FACS, FAANSDean, University of Oklahoma College of Medicine / Prof. of Neurosurgery / Chief Academic OfficerПотвърден имейл адрес: ouhsc.edu
Margaretha GM RoemerPost-doc, Amsterdam UMC, location VUmcПотвърден имейл адрес: vumc.nl
Malak Abedalthagafi, MDProfessor and Director of NeuropathologyПотвърден имейл адрес: emory.edu
W. K. Alfred YungUT MD Anderson Cancer CenterПотвърден имейл адрес: mdanderson.org
Donna NeubergDana-Farber Cancer InstituteПотвърден имейл адрес: jimmy.harvard.edu
Rebecca FolkerthNYU Grossman School of MedicineПотвърден имейл адрес: nyulangone.org
Lynette ShollBrigham and Women's HospitalПотвърден имейл адрес: bwh.harvard.edu
Michelangelo FiorentinoChief Molecular Oncologic Pathology, S.Orsola-Malpighi HospitalПотвърден имейл адрес: aosp.bo.it
Sean TavtigianProfessor of Oncological Science, University of UtahПотвърден имейл адрес: hci.utah.edu
charles eberhartProfessor of Pathology, Ophthalmology and Oncology, Johns Hopkins University School of MedicineПотвърден имейл адрес: jhmi.edu
Michelle HirschBrigham and Women's Hospital, Harvard Medical SchoolПотвърден имейл адрес: bwh.harvard.edu
Levi GarrawayAssociate Professor of Medicine, Harvard Medical SchoolПотвърден имейл адрес: dfci.harvard.edu
David RowitchUniversity of Cambridge and UCSFПотвърден имейл адрес: peds.ucsf.edu
Alvin KhoBoston Children's HospitalПотвърден имейл адрес: hms.harvard.edu

Следене

Azra H. Ligon, PhD, FACMG

Brigham & Women's Hospital/Harvard Medical School

Потвърден имейл адрес: bwh.harvard.edu

Cancer cytogenetics


Заглавие Сортиране по цитати Сортиране по година Сортиране по заглавие	Позовавания Позовавания	Година
The landscape of somatic copy-number alteration across human cancers R Beroukhim, CH Mermel, D Porter, G Wei, S Raychaudhuri, J Donovan, ... Nature 463 (7283), 899-905, 2010	4441	2010
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers PA Steck, MA Pershouse, SA Jasser, WKA Yung, H Lin, AH Ligon, ... Nature genetics 15 (4), 356-362, 1997	4161	1997
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma SM Ansell, AM Lesokhin, I Borrello, A Halwani, EC Scott, M Gutierrez, ... New England Journal of Medicine 372 (4), 311-319, 2015	4049	2015
Recurrent BRAF mutations in Langerhans cell histiocytosis G Badalian-Very, JA Vergilio, BA Degar, LE MacConaill, B Brandner, ... Blood, The Journal of the American Society of Hematology 116 (11), 1919-1923, 2010	1298	2010
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis JW Locasale, AR Grassian, T Melman, CA Lyssiotis, KR Mattaini, AJ Bass, ... Nature genetics 43 (9), 869-874, 2011	1212	2011
Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study AM Lesokhin, SM Ansell, P Armand, EC Scott, A Halwani, M Gutierrez, ... Journal of clinical oncology 34 (23), 2698-2704, 2016	1081	2016
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, ... The lancet oncology 17 (9), 1283-1294, 2016	1022	2016
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome YJ Cho, A Tsherniak, P Tamayo, S Santagata, A Ligon, H Greulich, ... Journal of clinical oncology 29 (11), 1424-1430, 2011	860	2011
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome MGM Roemer, RH Advani, AH Ligon, Y Natkunam, RA Redd, H Homer, ... Journal of Clinical Oncology 34 (23), 2690-2697, 2016	829	2016
CDK8 is a colorectal cancer oncogene that regulates β-catenin activity R Firestein, AJ Bass, SY Kim, IF Dunn, SJ Silver, I Guney, E Freed, ... Nature 455 (7212), 547-551, 2008	817	2008
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma DY Chiang, A Villanueva, Y Hoshida, J Peix, P Newell, B Minguez, ... Cancer research 68 (16), 6779-6788, 2008	781	2008
Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma U Schüller, VM Heine, J Mao, AT Kho, AK Dillon, YG Han, E Huillard, ... Cancer cell 14 (2), 123-134, 2008	737	2008
Targetable genetic features of primary testicular and primary central nervous system lymphomas B Chapuy, MGM Roemer, C Stewart, Y Tan, RP Abo, L Zhang, AJ Dunford, ... Blood, The Journal of the American Society of Hematology 127 (7), 869-881, 2016	558	2016
Mechanisms and therapeutic implications of hypermutation in gliomas M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu, CL Bohrson, ... Nature 580 (7804), 517-523, 2020	527	2020
Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma AM Fontebasso, S Papillon-Cavanagh, J Schwartzentruber, H Nikbakht, ... Nature genetics 46 (5), 462-466, 2014	462	2014
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors AJ Wagner, I Malinowska-Kolodziej, JA Morgan, W Qin, CDM Fletcher, ... Journal of clinical oncology 28 (5), 835-840, 2010	459	2010
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial J Fangusaro, A Onar-Thomas, TY Poussaint, S Wu, AH Ligon, ... The lancet oncology 20 (7), 1011-1022, 2019	443	2019
Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer EP Garcia, A Minkovsky, Y Jia, MD Ducar, P Shivdasani, X Gong, ... Archives of Pathology and Laboratory Medicine 141 (6), 751-758, 2017	431	2017
Institutional implementation of clinical tumor profiling on an unselected cancer population LM Sholl, K Do, P Shivdasani, E Cerami, AM Dubuc, FC Kuo, EP Garcia, ... JCI insight 1 (19), 2016	394	2016
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications D Dias-Santagata, Q Lam, K Vernovsky, N Vena, JK Lennerz, DR Borger, ... PloS one 6 (3), e17948, 2011	376	2011

Системата не може да изпълни операцията сега. Опитайте отново по-късно.

Статии 1–20

Позовавания годишно

Дублирани описания

Обединени библиографски описания

Добавяне на съавториСъавтори

Следене

Позовавания

Съавтори